Tuesday, June 7, 2011

BioMarin starts Phase III trial in rare LEMS disease

BioMarin Pharmaceutical Inc. started a late-stage trial of an experimental drug to treat a rare autoimmune disease called Lambert-Eaton Myasthenic Syndrome, or LEMS.
The Phase III trial will test Novato-based BioMarin’s (NASDAQ: BMRN) amifampridine phosphate in about 30 patients across 25 sites worldwide, the company said.

No comments:

Post a Comment